This study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS.

Chronic heart failure(CHF) is a serious public health problem in the world, which occurs mostly in the elderly,with extremely high morbidity and mortality. The physiological changes in the cardiovascular system caused by aging are an independent risk factor for CHF. For this reason, effective drug treatment is often used to improve the clinical symptoms and quality of life of older CHF patients, and ultimately achieve the goal of reducing hospitalization rate and cardiovascular mortality. This article describes recent progress of drug therapy for older patients in chronic heart failure. Keywords: Aging, older patients, chronic heart failure, drug therapy

Objective: To study the possibility and characteristics of long-term standard dose statin-induced stenosis regression in middle-aged and elderly patients with coronary heart disease (CHD). Methods: The study patients were those with CHD admitted to our hospital from 2010 to 2019. All patients underwent computed tomography angiography (CTA) scanning and were diagnosed with a regression of stenosis. Results: Thirty-one patients (24 males and 7 females) with an average age of 64.7±1.8 years were reexamined by CTA at a mean of 18.6±1.9 months after the initial examination. The left anterior descending (LAD) coronal artery stenoses were significant regressed. Conclusion: In middle-aged to elderly patients with CHD, a long-term and standard dose statin treatment may lead to the regression of coronary artery stenosis. Key Words: Coronary atherosclerosis, statin, coronary CT angiography, middle-aged and elderly.